Product
BioVaxys is leveraging its haptenized antigen technology platforms to develop vaccines to potentially treat viral infections such as SARS-CoV-2, human papillomavirus (HPV), cancers such as late-stage ovarian cancer, cervical cancer and melanoma.
CoviDTH® The world’s first low cost, disposable, diagnostic to identify a T-cell immune response to the presence of SARS-CoV-2.
Because T-cell mediated immunity to SARS-CoV-2 is as important as an antibody response.
Learn More About CoviDTH®